Form 4: Bristol-Myers Squibb Exec's Routine Stock Activity

Bristol-Myers Squibb EVP Cari Gallman reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Summary

• Cari Gallman, Executive Vice President and General Counsel of Bristol-Myers Squibb Company (BMY), reported transactions on August 1, 2025.
• Acquired 1,061 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Disposed of 543 shares of common stock at a price of $44.23 per share to cover tax obligations associated with the RSU vesting.
• Following these transactions, Gallman directly holds 8,840 shares of common stock and 1,061 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, including RSU vesting and tax-related share sales, which are neither significantly positive nor negative for the company's outlook.

Positives

• Executive ownership of company stock aligns management interests with those of shareholders.
• The vesting of Restricted Stock Units indicates the achievement of performance or tenure milestones by the executive.

Negatives

• A portion of shares were sold, reducing the executive's direct ownership, although this was for tax purposes.

Future Outlook

The reported Restricted Stock Units are part of a vesting schedule that began on August 1, 2024, with the specific tranche reported having an expiration date of August 1, 2026.

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion, but also alignment of executive interests with shareholder value.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Continued vesting of remaining Restricted Stock Units according to the established schedule.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and subsequent share sales for tax purposes. It does not present new information that would alter the fundamental investment thesis for Bristol-Myers Squibb, thus a 'hold' recommendation is appropriate.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, Executive Compensation, Cari Gallman